Porphyria Cutanea Tarda clinical trials at UCSF
1 in progress, 1 open to new patients
open to eligible people ages 18 years and up
In the medical literature there case reports that Harvoni improves symptoms in patients with PCT. However, this has never been systematically tested. Therefore, the purpose of this study is to assess whether Harvoni alone is an effective therapy of active PCT in patients with Chronic Hepatitis C.
San Francisco, California and other locations